Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IHL-216A
- Development stage
- Unknown
- Lead developer
- Incannex Healthcare
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
IHL-216A is a proprietary combination drug developed by Incannex Healthcare. It consists of cannabidiol (CBD) and isoflurane (ISO), formulated for inhalation. The drug is designed to be administered soon after head trauma to reduce secondary brain injuries that can lead to neurological deficits, such as those seen in traumatic brain injury (TBI) and concussion. Preclinical studies have demonstrated that IHL-216A has neuroprotective effects, restoring spatial memory and reducing neuronal damage more effectively than either CBD or isoflurane alone in animal models of TBI and sports-related concussion. The mechanism involves the combined neuroprotective actions of CBD—a non-intoxicating cannabinoid with anti-inflammatory and antioxidant properties—and isoflurane, a volatile anesthetic known for its neuroprotective potential when used acutely after injury[1][2][3][4][5][6][7][8].
- Brand names
- IHL-216AIHL216AIHL 216A
02
Targets
GABRR (GABA-A receptor subunit rho)CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on IHL-216A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IHL-216A.